• Generated $1.14M in revenue in Q1-FY2022 (quarter ended October 31, 2021), up 83% YoY, and 11% QoQ, but missed expectations as we were expecting stronger revenues from cannabis 2.0 products.
            • This report is currently available to premium subscribers – Free subscribers will gain access on December 22nd, 2021
              Join as a FREE member and get our research report delivered straight to your inbox, with a seven-day delay

Visit THC BioMed Intl Ltd. page for more research, discussion boards and to like, and share.

Download Analyst Report :

Investors are also interested in: